difference in OS, a small subgroup of these patients with low pre-treatment ALC had prolonged ongoing CR. The reasons for the differences between our cohort and that reported by Porrata et al. are unclear, as is the consideration of whether prior treatment affects outcome, despite both groups including heavily pretreated patients. Possibilities for the differences observed include our use of the chimeric anti-CD20 antibody rituximab for RIT, which is cleared from the circulation at a slower rate than murine antibodies, as well as the use of 131 Iodine as a radioisotope rather than 90 Yttrium. However, it is difficult to conceptualize how these minor differences in an otherwise similar treatment modality would result in such a marked divergence in outcome. Both studies are retrospective analyses from single institutions. We would suggest that in contrast to the proposal of Porrata et al., the ALC cannot yet be used as a stratification factor for tumor response and TTP following RIT and should not be used to select patients for such therapy. The potential prognostic role of ALC, and specifically subset analysis of regulatory, cytotoxic and helper T cells, natural killer cells, and indeed the putative role of ADCC more generally in the therapeutic activity of RIT, will need to be clarified in the context of prospective clinical trials. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory nonHodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital.
Reply to 'Claimed association of absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independence data set' by Mark J Bishton et al Leukemia (2008) We read with interest the study by Bishton et al. 1 evaluating the role of absolute lymphocyte count (ALC) on survival and response rate in a cohort of 35 patients with indolent nonHodgkin lymphoma treated with 131 I-rituximab. In contrast to our previous publication, 2 Bishton et al. reported an improved time to progression and better likelihood to achieve a complete response in patient with an ALC o1.0 Â 10 9 /l after treated with radio-immunotherapy (RIT).
The pressing question based on the study by Bishton and co-workers and our study is if the ALC is the best marker of host immunity affecting survival in patients treated with RIT. The ALC, as a surrogate maker of host immunity has been reported to be a significant factor for survival for different hematological 3 and solid tumor malignancies, 3 at diagnosis, 4 during standard chemotherapy, 5 as well as after autologous stem cell transplantation. 3 Moreover, ALC is a prognostic factor for survival not only in the adult setting, but also in the pediatric setting. 6, 7 A limitation of the ALC is that the ALC does not identify the specific lymphocyte subset affecting survival. Besides both studies being retrospective, a major limitation of both studies is the lack of lymphocyte subset analysis to further delineate which lymphocyte analysis might affect survival post-RIT and by which immunological mechanism.
Is the ALC lymphocyte subset analysis important? The obvious answer is yes. Recent reports have shown that the ALC at diagnosis in patients with diffuse large B-cell lymphoma is a prognostic factor for survival. 8 In the French study (LNH98B3), 9 diffuse large B-cell lymphoma patients that at diagnosis had a higher NK cell count, and not the ALC, experienced superior survival compared to those who did not. So that fact that the study by Bishton et al. identified that patient with Letters to the Editor an ALC o1.0 Â 10 9 /l tended to do better does not discredit the role of the host immunity in affecting survival in patients treated with RIT, as it might be the possibility that in their low ALC group there was higher NK cells numbers explaining the observed better outcome. Therefore, we agree with the authors that prospective studies are warranted to address these issues. 8 and coxsackievirus A21. 9 Our lab has previously developed an attenuated, recombinant double-deleted vaccinia virus (VV) that infects, replicates and expresses genes preferentially in rapidly dividing tumour cells. 4 We asked whether VV would be an effective oncolytic virus against MM.
LF
Initially, fluorescence-activated cell sorting analysis was used to quantitate the percentage of enhanced green fluorescent protein (EGFP)-positive MM cells after infection with an EGFPexpressing VV. All five cells lines were infected (Figure 1a) . After 72 h, RPMI8226 was most efficiently infected and U266 was the least efficient. To confirm that VV infection and gene expression in MM cell lines led to oncolysis and cell death, MM cell lines were infected with VV at a multiplicity of infection (MOI) of 1, and MTT assays were performed (Figure 1b) . Compared to mockinfected controls (100% viable), all cell lines showed decreased viability from 17 to 29% at 72 h. To validate the MTT assays, a trypan blue exclusion assay was performed with similar results (Supplementary Figure S1) . In vitro oncolysis, as measured by an assay to detect cytopathic effects, was visible by 48 h (Figure 1c) after infection for the majority of cell lines. This was delayed for the U266 and H929 cell lines suggesting that these cell lines are less susceptible to VV-mediated cell killing though both were infected and express EGFP (Figure 1c, bottom panel) .
As many anti-myeloma therapeutics act through the induction of apoptosis in MM cells, we asked whether VV-mediated cell death was due to a similar mechanism. Annexin V staining was used to quantitate the number of cells undergoing apoptosis. Compared to mock infection alone, VV infection induced apoptosis in four of five cell lines by 72 h (Supplementary Figure S2) . The number of necrotic cells was also increased over mock infection.
We next evaluated VV-mediated oncolysis in established tumours after systemic delivery. My5 subcutaneous xenograftbearing mice were treated with systemic (intraperitoneal, 10 9 plaque-forming unit (PFU) per mouse) VV or vehicle control. After treatment with a single dose of VV, the growth of My5 (Figure 2a ) xenografts was significantly (Po0.0001) inhibited by the treatment compared to vehicle control. In addition, My5-bearing mice re-treated with a second dose of VV showed further tumour regression. Selected mice underwent fluorescent imaging at various time points after infection with the EGFPexpressing VV. Viral-mediated EGFP expression was minimal 6 days after VV infection, but slowly spread throughout the tumour and peaked 3 weeks post-infection (Figure 2b ).
